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Patient registries are an essential tool to increase current knowledge regarding rare diseases. Understanding these data is a vital
step to improve patient treatments and to create the most adequate tools for personalized medicine. However, the growing number
of disease-specific patient registries brings also new technical challenges. Usually, these systems are developed as closed data silos,
with independent formats and models, lacking comprehensive mechanisms to enable data sharing. To tackle these challenges,
we developed a Semantic Web based solution that allows connecting distributed and heterogeneous registries, enabling the
federation of knowledge between multiple independent environments. This semantic layer creates a holistic view over a set of
anonymised registries, supporting semantic data representation, integrated access, and querying. The implemented system gave
us the opportunity to answer challenging questions across disperse rare disease patient registries. The interconnection between
those registries using Semantic Web technologies benefits our final solution in a way that we can query single or multiple instances
according to our needs. The outcome is a unique semantic layer, connecting miscellaneous registries and delivering a lightweight
holistic perspective over the wealth of knowledge stemming from linked rare disease patient registries.
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1. Introduction
A rare disease is a particular health condition affecting at
most 1 in 2000 patients [1]. According to the Orphanet inven-
tory (http://www.orpha.net/), there are approximately 6000
to 8000 rare diseases, from which about 80% have a genetic
origin. Complex health implications behind rare diseases are
seldom considered inmedical or social care. Due to the rarity
of each individual disease and their often-complex nature,
this group is underrepresented in research and treatment
developments. At the patient level, the diagnosis of a rare
disease generally means higher difficulty to find support,
both clinical and psychological [2]. The existence of a small
number of cases for each disease creates additional barriers in
the translational research pathway, as it is difficult to identify
and coordinate a substantial cohort [3, 4]. Nevertheless,
altogether rare disease patients comprise an estimated 6 to
8% of the EU population [5]. During the last decade, several
small disease-specific databases were developed, related, for
instance, to neurological disorders or muscular problems [6].
While they provide high quality information and resources,
their disease coverage is small and typically with a regional
or national scope. To achieve higher statistical evidences,
we need more extensive cohorts of patients with similar
features, from worldwide population. Hence, discovering
rare disease causing genes can have impact on all medical
treatment stages, from clinical diagnostics to insights gained
into biological mechanisms and common diseases [7].
In addition to long-term patient care improvements,
understanding gene-disease associations is a fundamental
goal for computational biology research, especially in rare
disease where genotype-phenotype connections are typically
limited to one or a few more genes [8, 9]. Moreover, it is
in these particular conditions that the strongest relations
between genotypes and phenotypes are identified. Hence,
to fully understand the underlying causes of diseases, we
need to connect knowledge that is widespread throughout
miscellaneous registries.
Rare disease patient registries are typically fragmented by
data type and disease. Furthermore, these systems have poor
interoperability due to the high complexity and heterogeneity
of data types and the lack of using standards on data model
and data descriptions. Coupled with severe requirements to
protect data, the access to the patient’s registries is restricted,
converting these valuable and distributed sources in closed
data silos. This poses a barrier for linking patient-centric
electronic records across registries and across diseases. To
tackle these integration barriers, we started the study looking
for relevant questions difficult to answer without an infras-
tructure of integrated patient data from several registries.The
motivating questions were, for instance,
(1) Given a set of phenotypes that are relevant for
neuromuscular (e.g., DM, FSHD, LGMD2I) and neu-
rodegenerative diseases (e.g., HD,Ataxia), canwe find
patients in a disease nonspecific way?
(2) More specifically, based on “Ambulation”, “Age”, and
“Country”, can we get the number of patients?
Answering this kind of questions requires data of disparate
nature and from multiple sources. To harmonize these data
into a semantic layer we need an integration platform capable
of converting any data format into RDF.This implies abstract-
ing registry concepts and their attributes, such as Patient
(sex, birthday, and country); Disease; Phenotype (motor,
ambulation); and Genetic Variation and then representing
them into a graph data model in which the semantics of the
objects and their relationships can be describedwith standard
or widely adopted ontologies. Finally, patient registries data
should be aggregated by concept. In each concept, data
elements, or instances that represent the same entity but have
different text mentions in each registry, must be mapped
to an ontology term. For example, Orphanet Rare Disease
Ontology (ORDO) for diseases and the Human Phenotype
Ontology (HPO) for phenotypes can be used to make data
interoperable and linkable in the Web of data. The use of
domain-specific and commonly used ontologies adds value to
data, through an integrated knowledge base that is searchable
and comparable by user and by machines [10]. Furthermore,
interlinking patient registry datawith external linked datasets
allows enriching the current knowledge in the rare disease
research.
In this work, we have developed a new semantic layer
on top of existing patient registries, to allow extract-
ing anonymised data from the original datasets, translate
them to a common shared exchange model, and make
them available to the research community (available at
http://bioinformatics.ua.pt/linked-registries-app/). The solu-
tion addresses three key requirements from the patient
registries research community: (1) data model agnostic; (2)
distributed and encapsulated; and (3) knowledge-oriented.
Firstly, data harmonization strategies are data model
agnostic and work regardless of registries’ data format and
internal structure. This is clearly important as we are dealing
with systems featuring assorted characteristics, from rela-
tional databases and service endpoints, up to Excel spread-
sheets.
Next, the solution is distributed and encapsulated. When
dealing with rare disease patients, it is imperative to ensure
data anonymity and privacy.Hence, we need tools that extract
meaningful data while maintaining hidden all the attributes
that may disclose patients’ identification.
At last, our approach takes advantage of Semantic Web
technologies to improve how we publish, access, express,
and share knowledge across the Web. From a technological
perspective, the system was built on top of COEUS [11],
an application framework that streamlines data integration
with semantic representation. As patient registries are shared
within this platform, researchers and developers are able to
perform federated queries, coveringmiscellaneous databases,
just like they would query a single local dataset.
In summary, we explore a Semantic Web approach and
a nonintrusive strategy to interconnect, enrich, and federate
data from multiple patient registries, allowing extending the
knowledge behind these distributed repositories.
2. Background
2.1. Patient Registries. The collection and maintenance of
patient registers have been assuming a key role in the
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identification of new treatments and in the improvement of
care. In particular, personal genetic records are of growing
interest. These data are increasingly important for diagnosis,
resolution, and therapeutic treatment of rare diseases. Hence,
databases with information about human genome, such
as the Human Gene Mutation Database (HGMD) [12] or
the 1000 Genomes Project [13], currently have a growing
relevance. Moreover, it is important to reuse these data in
novel biomedical software to enable its usage on dailymedical
workflows.
The value of individual data increases when it is aggre-
gated and presented in a unified way, both for humans
and computers [14]. Orphanet provides a public portal, for
professionals and patients, with the most updated informa-
tion about rare diseases and orphan drugs [15]. It also dis-
plays information on specialized consultations, diagnostics,
research projects, clinical trials, and support groups. Dis-
easecard [16] is another platform that aggregates genotype-
to-phenotype information regarding rare diseases, pointing
to key elements for both the education and the biomedical
research field. While these systems do not provide reposito-
ries for patient-level data, they are useful resources for sharing
and disseminating existing knowledge and expertise.
Besides the important role of these specialized reposi-
tories, the integration of knowledge that can be extracted
from distinct electronic health records (EHRs) is also a major
challenge to support personalized medicine. Data from gene
sequences, mutations, proteomics, and drug interactions (the
genotype) can now be combined with data from EHRs,
medical imaging, and disease-specific information stored
in patient registries (the clinical phenotype). Hence, it is
crucial to start exploring patient-level data from rare diseases
registries, which often include personal data, diagnosis, clin-
ical features, phenotypes, genotypes, treatments, and clinical
follow-up.
According to Orphanet, there are over 600 rare disease
registries just in Europe, with different aims and objectives,
with access to different resources and collecting different
datasets. Registries have traditionally been developed to
accelerate the translational research pathway helping tomove
therapies from bench to bedside as quickly as possible. They
provide a tool for the feasibility and planning of clinical trials
as well as means to identify and recruit patients into research.
However, the purpose and utility of registries has a much
broader reach providing a source of natural history data and
a basis for hypothesis generation that can advance research
into a given field.
A single academic can set up a registry or a clinician with
an interest in a particular field, or a disease network, or—as is
increasingly common—a patient organization.The variety in
origin explains the variety of funding schemes (sustainability
models) and data collection techniques [17].
The highly developed registries (e.g., Cystic Fibrosis
[18, 19]) act as detailed natural history studies, with data
collected at fixed time points in the clinical setting and stored
in bespoke software solutions. However, many registries
are online self-report systems, with patients entering data
through aWeb portal.There are also examples of a combined
approach: patients initiate registration, while physicians ver-
ify details through the same Web portal. This disparity in
data collection increases the complexity of a unified system.
The data items themselves are not standardized across all
rare diseases though a significant amount of effort has been
applied in this area. Some consensus has been reached in
certain disease areas, such as DuchenneMuscular Dystrophy
(DMD), where a federated registry system exists under the
umbrella of TREAT-NMD (http://www.treat-nmd.eu/) [20,
21].
One step towards harmonization can come in the form
of international medical classifications or languages, such
as UMLS [22] or SNOMED-CT [23], among some other
terminologies, and, more recently, the use of phenotype
ontologies, such as HPO [24], has been proposed as a tool
for phenotype standardization. Ontologies are structured
representation of knowledge using a standardized, controlled
vocabulary for data integration, organization, searching, and
analysis. The use of ontologies to identify and annotate
data in patient registries ensures interoperability and access,
and it also enables cross-cohort comparisons and filtering.
Importantly, it allows the development of new bioinformatics
tools, covering the automated and systematic matching of
clinically similar representations of phenotypes to assist in
differential diagnosis, among others.
These patient-centric databases offer unique specialized
views over their internal datasets. However, while there
are huge amounts of data scattered throughout multiple
stakeholders, they are wildly difficult to obtain or access. The
main reasons are the lack of semantic compatibility and the
evident low motivation of data owners to share and spread
their valuable datasets and, thus, individual efforts remain
isolated. This is a critical hindering factor in rare disease
research, where a sole centremay collect only a small number
of patients with a certain disease. The outcome of this is that,
in the end, there is not enough data to generate statistically
meaningful conclusions. As such, we cannot discover or infer
new knowledge because there is no access to a minimal
amount of patient data.
To cope with these challenges we need a platform that
offers a unique holistic view promoting the collaboration of
multiple entities towards the study of rare diseases and assess-
ment of patients’ evolution [25]. According to our study, only
one related exchange platform was developed regarding the
rare diseases domain: The Matchmaker Exchange [26]. This
platformprovides a systematic approach to create a federation
network of genotypes and phenotypes databases through
a common application programming interface (API). This
helps in the process of finding common genotype/phenotype
pairs inmultiple individuals. However, this approach requires
deposition of the data into the main database or the setup of
local instances, always ensuring a set of services and end users
agreements. Comparatively, our proposed solution is more
generic and suitable for the creation of independent systems
that can be plugged into any existing patient registry without
changing it. Furthermore, as our system relies on Semantic
Web technologies and standards, this will promote a better
translation, federation, and discovery of new knowledge. By
exploring the Matchmaker system (and its different aims),
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we believe that our approach is a better milestone towards
semantic interoperable rare diseases knowledge.
2.2. Semantic Web. The Semantic Web arises as a ground
breaking paradigm to foster the intelligent integration of
structured information. Sustained by state-of-the-art stan-
dards such as RDF, OWL, SPARQL, and LinkedData, the
SemanticWebpromotes better strategies to express, infer, and
make knowledge interoperable.
Latest advances in the area cover the research and
development of new algorithms to further improve how
we collect data, transform data into meaningful knowledge
assertions, and publish connected knowledge. State-of-the-
art solutions, including the EBI RDF Platform [27], COEUS
[11], or SADI [28], pave the way towards interoperable
scientific knowledge. From a large-scale perspective, we can
now see the Semantic Web as a single knowledge network.
Available technologies foster data integration and publishing,
enabling an effortless connection between heterogeneous
distributed knowledge.
The true value behind Semantic Web technologies lies in
on how easy it is to access and exchange knowledge between
independent systems. The Linked Data guidelines, from the
W3Cworking group, promote accessing data via uniqueURIs
that, besides identifying knowledge, must resolve to real data.
SPARQL, the Semantic Web query language, complements
Linked Data.
Knowledge bases with an open SPARQL endpoint enable
direct queries to their content. This empowers researchers
and developers alike with an open knowledge highway. In
this area, COEUS can play a fundamental role by delivering
a “Semantic Web in a box” approach, enabling the rapid
development of new knowledge management systems with
Semantic Web technologies [29, 30]. COEUS allows gather-
ing data from heterogeneous repositories and publishes them
via SPARQL endpoint and Linked Data interfaces.
3. Methods
3.1. Architecture. Semantic data integration is, in itself, a
complex data engineering issue if we have to code every
component of the software solution [31, 32]. Leveraging
on previous results [33], we use COEUS as the baseline
framework of our platform. Exploring its flexible integration
engine enables simplifying the overall platform architecture
through the creation of a comprehensive dependency-based
resource integration network.
Figure 1 presents the platform’s distributed architecture,
which is organized in four levels: (1) Patient, (2) Semantic,
(3) Federation, and (4) Research.
At the patient level we gather information from the
distributed and heterogeneous patient registries, which can
be stored in multiple formats using various technologies
(e.g., relational databases, text files, and spreadsheets). Patient
registries can be integrated in the framework regardless of
their location and their quantity.
At the second level we include additional semantics to
patient registries data.This is done using COEUS, which acts
as themain abstraction, storage, and publishing engine. Here,
we manage the anonymised patient data, translating from
their primitive format to common biomedical ontologies.
The third level provides the knowledge federation and
data exploration capabilities; that is, SPARQL queries can
be forwarded to several patient registries endpoints. COEUS
acts here as a middleware component between the patient
registry triple store and the public knowledge federation layer.
Finally, at the upper level researchers can perform general
queries that combine data fromone ormore patient registries.
In a sense, query federation enables performing SQL-like
UNIONs or JOINs across multiple knowledge bases. This
empowers knowledge inference and reasoning queries to go
beyond what is currently possible.
3.2. Workflow. Publishing anonymised patient registries data
in a semantic way requires a comprehensive workflow. Fig-
ure 2 describes the key steps in this semantic integration and
translation pipeline: (1) ontologymapping; (2) COEUS setup;
(3) semantic translation; and (4) data publishing.
The first step consists in defining the best ontologies to
map common patient’s data. HPO [24], UMLS [34], ICD
[35], and ORDO [15] are the most widely used ontologies in
the rare diseases field. One of the great advantages of using
Semantic Web technologies is that any external ontology can
be used to complement or extend COEUS internal model. As
long as clinicians understand the new predicates, any number
of properties can be included, semanticallymapping concepts
or entities to existing ontologies or adding further properties
to describe entities or concepts. Moreover, we may combine
multiple ontologies, that is, the same data element can be
mapped to terms from more than one ontology, optimising
its expressiveness and enriching the way it can be used in
future research environments. In this step, semiautomated
annotation tools such as SORTA [36] and EGAS [37] along
human curation experts play an important role for the
annotation of biomedical data (e.g., phenotypes, diseases).
The second step of the pipeline consists in the configura-
tion and deployment of a new COEUS instance. The setup
involves defining how data will be extracted and mapped
into the selected ontology terms. Using COEUS connectors
we have to specify where the data comes from (Excel,
CSV, or XML files; SQL databases; or SPARQL/LinkedData
endpoints) and how we will map it to the ontologies. For
instance, for a patient registry available as a CSV file, we need
to specify the file location and, for each mapped ontology
term, the column containing the actual data elements.
In the following stage, the semantic translation process,
knowledge base elements, and their data and object proper-
ties are created in real-time from the integrated data. This
step elevates data in primitive formats to a new semantic
abstraction level. The process is complete when all data are
imported into a new triple store, making it available for
external use through the various data publishing endpoints.
3.3. Implementation. COEUS framework is focused on help-
ing researchers in the construction and publishing process
of new semantically enhanced systems. It offers a good
starting point to integrate disparate data due to the advanced



















Figure 1: Knowledge federation architecture, integrating distributed patient registries via COEUS.
ETL (Extract-Transform-Load) processes in its engine.These
algorithms facilitate the “triplification” process, in which
all data are converted to a simple subject-predicate-object
model. Moreover, it makes the integrated information avail-
able through a hierarchical model establishing relationships
between data in an “Entity-Concept-Item” structure (e.g.,
Protein-Uniprot-P51587). To create each registry’s knowledge
base according to this organized model, we must fulfil some
initial requirements. Essentially, there are three main steps
to achieve the final solution: the first is data selection, the
second is the data sources configuration, and last one is the
data integration process. In the first step, we have applied
a preselection process to all registries data. In this process,
we select the desired information for our study avoiding
sensitive data and considering only nonidentifiable data.
Patient registries have a lot of information, but some are
redundant and incomplete. Regarding that, applying this
initial filtering process is vital to build a consistent database.
This process was only possible due to the involvement of
respective data owners that translated what their data means.
In the final stage of this initial filtering process, we exported
the files of the distinct registries. Each dataset was imported
to a separated COEUS instance, as we plan to have four
distributed systems. In the second step, we define the data
sources attributes for each registry. This starts by creating
one Resource (Figure 2, block 1—ontology mapping) in the
knowledge base that contains the respective data elements
such as Endpoint location (i.e., the registries file location),
Publisher (i.e., CSV file), CSV Starting line (i.e., 1 as the
registries file has headers), and Method (i.e., cache as we
will load the entire file into the system). Additionally, for
each Resource, a combination of parameters (i.e., Selectors)
must also be included to establish the mapping between the
information to be extracted from the registry (e.g., for each
column) and the respective formal ontology terms that con-
nects it. For instance, we can make use of the Human Disease
Ontology [38] term has symptom to establish the connec-
tion between a Facioscapulohumeral Muscular Dystrophy
(FSHD) patient and the identified symptoms: coeus:Patient X
doid:has symptom obo:HP 0001324 (i.e., muscle weakness.).
Likewise, we link each patient to its respective identifier by
creating a Selector that makes the linkage between the CSV
first column (with the patient IDs) in the parameter query
and the property dc:identifier from theDublin CoreOntology
[39]. Establishing all these mappings in the registries records
makes the foundation of an interconnected network of rela-
tionships between patients and respective features possible.
An overview of the knowledge base model is available in
Figure 3, showing a simplified view of Facioscapulohumeral
Muscular Dystrophy Type 1 (omim:158900) patients relation-
ships.
After these configurations, the last process encompasses
the automatic integration and semantic mapping of data
sources. To expose data, we provide several interoperability
features such as SPARQL endpoint and a Linked Data
interface. The SPARQL endpoint works as a federated query
system, in which we can perform complex queries across
patient registries. The Linked Data interface provides easy
access to the patient information through the Web Browser
or similar applications.
All the described processes aremanaged throughCOEUS
Web user interface that provides an easy-setup solution to the
installation and configuration process.
4. Results
4.1. Exploring Rare Diseases Patient Registries. Neurodegen-
erative and neuromuscular diseases are among the most
frequent of rare diseases, affecting the life and mobility
of more than 500,000 patients and families in Europe
(http://rd-neuromics.eu/). We used the proposed architec-
ture for the integration of four patient registries in the
neuromuscular and neurodegenerative disease area. These
registries collected patient data from ten different countries
(United Kingdom, Italy, Spain, Denmark, France, Nether-
lands, Sweden, Austria, United States, and Germany) and












































Figure 2: Simplified registry publication workflow.
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Figure 3: Patient registry model overview. Facioscapulohumeral Muscular Dystrophy patients share concepts and relationships, creating a
fully connected network.
gather information related to four rare diseases: Myotonic
Dystrophies (DM), Facioscapulohumeral Muscular Dystro-
phy (FSHD), Fukutin Related Protein (FKRP) related condi-
tions (e.g., LGMD2I), and Huntington’s Disease (HD).
To first guide the development of our solution and also, at
the end, to allow its validation, several questions were initially
elaborated:
(1) Can we find more than ten male and ten female
patients that share a set of phenotypes and live in
different countries?
(2) To build a trial/research data set, how many patients
have the desired conditions/requirements for the
study and live closest to the clinical/research setting?
(3) What are the phenotypes associated with Myotonic
Dystrophies (DM) and Facioscapulohumeral Muscu-
lar Dystrophy (FSHD) diseases?
(4) Are there patients treated with different therapies
diagnosed with the same disease?
(5) Are there patients treated with the same therapy but
diagnosed with different diseases?
(6) Can we find patients diagnosed with a certain disease
with different states of morbidity?
(7) Are there patients with this specific set of phenotypes?
(8) Are there patients sharing phenotypes and diagnosed
with different neuromuscular and neurodegenerative
diseases?
To find the answers for these questions researchers and
clinicians need to look for patient data that are fragmented in
different registries and need to combine data across registries
and across diseases. Without an infrastructure of integrated
patient registries, this is not a straightforward endeavour
because each patient registry is designed, described, and
technically implemented in a particular way, and data are
not connected. This means that to answer whatever of these
questions one will spend a considerable amount of time to
understand each registry data model, to access and retrieve
each registry’s needed data, to aggregate all registries’ data
in a meaningful manner, and, finally, to query-answer over
the harmonized data to extract the information. These are
rather inefficient and infeasible propositions. Thus, to gain a
complete view on a specific disease and patient population
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Figure 4: Linked Registries Web application interface.
of interest, and to retrieve the desired information to answer
these questions, the linking of registries data sets is an
essential step. The described research questions involved the
collaboration of data owners and database managers, which
participated actively in the data selection and harmonization
processes, and providing continuous feedback for the final
solution.
4.2. The Linked Registries Solution. The interconnection
between disperse patient registries using COEUS facilitates
our final solution in the way that we can query single
or multiple instances according to our needs. However, to
better access and enhance user interaction, we provide a
single and Web based entry point to access the aggregated
information available on each instance. This entry point is
available at http://bioinformatics.ua.pt/linked-registries-app/
and is based on a combination of SPARQL federation queries
templates with predefined variables. In each template ques-
tion, variables can be adjusted according to the knowledge
bases values automatically. All queries are generated in real-
time by the application and can be edited or adjusted (by
using the advanced mode) for a more accurate examination.
By using this solution, users have the opportunity to find
answers to the previously defined questions across disperse
patient registries. For instance, to answer the first question
we created a template federated query to retrieve results from
all the registries. As we store patient’s countries information
in each COEUS instance using the same model, we are
able to retrieve common characteristics from each instance.
Regarding that, finding a cohort sharing a set of phenotype
information and based in different countries can be done in
a straightforward process (Figure 4).
In order to answer this type of question, we searched
for male and female patients that have both “fatigue”
(i.e., obo:HP 0012378) and “muscle weakness” (i.e., obo:HP
0001324) phenotypes. By querying our system, we retrieved
male patients from six different countries, and female patients
from four different countries. Therefore, for our particular
set of registers, the number of patients (either in the male
or female case) living in different countries that share those
phenotypes is less than ten.
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Concerning question (2), filtering patient characteristics
according to some conditions, such as the use of gastric
tube on a Myotonic dystrophy type 1 (MD1) patient, can be
successfully performed. However, discovering patients living
closest to their clinical/research setting is not a trivial task to
perform due to the limitation of our registries’ data, which
only covers countries related information.
To answer inquiries similar to question (3) is also feasible.
For instance, we can query the two remote databases (e.g.,
FKRP and FSHD) through their SPARQL endpoint and
search for all shared phenotypes that have been registered
for patients suffering from Limb Girdle Muscular Dystrophy
2I (LGMD2I) and FacioscapulohumeralMuscular Dystrophy








SELECT DISTINCT ?phenotype {
SERVICE <FKRP-REGISTRY-SPARQL-
ENDPOINT>
{ ?patient FKRP ogdi:hasDisease
omim:607155.




{ ?patient FSHD ogdi:hasDisease
omim:158900.




In our case, the result of this query returned the
respective shared phenotypes for both diseases: “fatigue”
(obo:HP 0012378), “muscle weakness” (obo:HP 0001324),
and “rigidity” (obo:HP 0002063).
The same occurs for questions (4) and (5) as we have col-
lected information regarding patients’ diagnosis. This infor-
mationwas integrated according to the specifications for each
disease. However, we are able to cross information between
therapies and diseases due to our standardization strategy
based on community-shared and common ontologies in all
patient registries. For instance, if we query the different
registries looking for patients treated with “ACE inhibitors”
(i.e., ndfrt:N0000029130), we can easily find a correlation


































However, answering questions such as (6) is very complex.
The difficulty resides in finding structured patient’s states
of morbidity in each registry. Diseases states are usually
stored and described as long plain-text fields without suitable
structure, which makes the task of finding similarities in
that information more complex. Additionally, not all patient
registries have this type of information, creating barriers to
crossing information among different registries. Regarding
that, we do not integrate different states of morbidity of each
patient into our system.
In contrast, the two following questions, (7) and (8),
can be more easily answered due to the structured infor-
mation available regarding different diseases and respec-
tive patient phenotypes. To give an example for question
(7), we can randomly choose phenotypes such as “fatigue”
(obo:HP 0012378) and “muscle weakness” (obo:HP 0001324)
and simply count how many patients share both:






























obo:HP 0001324 } }
}
Using this schema allows us to find up to forty-one patients
spread along the different databases. To answer question (8),
we can also make a federated query to all registries to retrieve
a list of associations between phenotypes and diseases. Given
that, we are able to detect the most common associations by
counting the number of patient’s occurrences, in which the





SELECT ?phen ?disease (COUNT(DISTINCT



























} GROUP BY ?phen ?disease ORDER BY ?count
By querying our system, we are able to detect, for instance,
that phenotypes such as “Muscular weakness” (HP:0001324)
and “Fatigue” (HP:0012378) are more common in MUS-
CULAR DYSTROPHY (OMIM:607155) diseases and phe-
notypes such as “Myotonia” (HP:0002486) and “Fatigue”
(HP:0012378) are more representative in MYOTONIC DYS-
TROPHY 1 (OMIM:160900) diseases.
5. Discussion
The IRDiRC (International Rare Diseases Research) consor-
tium defined several overarching objectives, to achieve until
2020 [40]. Some of these goals include, for instance, to make
data accessible to the research community or to promote tools
and standards that simplify networking between data cen-
tres.The present solution was built upon these general needs,
offering an opportunity to access patients distributed data
in a common Web platform. The semantic layer approach
offers a technological solution that enables data andmetadata
sharing, following common ontologies and standards, as
described in the whole document. In our research work,
we identified how these Semantic Web technologies can
be tailored to the patient registries integration scenario.
Although our results are successful, they highlight two major
issues.
First, identifying the proper common ontology to be used
across patient registries is a cumbersome challenge. While
COEUS empowers this process at the technical level, there
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still has to be an agreement between stakeholders on what
ontologies will be used and how will their data be properly
mapped to them.This introduces a new challenge, as distinct
ontologies need to be adequately mapped [41]. In this point,
it is important to highlight that the creation of mappings
between patient registries elements and ontologies is a critical
point for data quality and reliability.
Rare diseases registry researchers frequently need to
extract the primary clinical information and translate it
into the registry data elements. This process is the key for
the validity of outcomes that are under the scope of the
registry. Both phenotypic information and final diagnosis
have to be derived from the clinical examination, genetic,
histopathological, and other laboratory tests, and radiological
images, among some other specific sources, which are all
challenging due to their heterogeneity and complexity.
In addition, standardization of the primary sources of
information is an important issue for registries, but, in some
situations, it is not possible. The translational process from
the real clinical status of the patient to the information
saved and stored into the registry database implies some
potential risk of introducing some bias information. The
establishment of mappings between information based on
ontological terms could lead us to obtaining standardized
data, but not valid results.Thus, when phenotypic data are not
well defined or it is incorrectly translated into the database
elements, this phenotypic information might be linked to
wrong ontological terms. Likewise, ontological terms are
not always as comprehensive as free text and, therefore, the
ability of an ontology to cover all phenotypic traits of specific
diseases is another limitation factor. In this regard, the
collaboration with ontology developers in order to expand
with further ontological terms and, hence, to align ontology
representations with the current knowledge is needed. This
active translational dialogue among the actors in the clinical
and research domains is important both to stimulate the use
of standards in patient registries and to ensure an appropriate
description of the current domain knowledge in biomedical
ontologies. In this challenging scenario, the mapping of
clinical terms has to be undertaken according to quality
procedures.
Nevertheless, several organizations are publishing com-
mon data element models in order to solve the interoper-
ability problem among different patient registries. Although
these efforts ensure interoperability within the selected
domain, interoperability across application domain bound-
aries is not automatically possible [42].
Furthermore, there are over 600 rare disease registries
in Europe alone, the majority not currently using a specific
ontology. Although there is an overall desire in the commu-
nity to increase harmonization, there is a lack of time and
resources to change established procedures.
Second, convincing data owners of the true value of shar-
ing their registry data is a cumbersome task. In addition to
the privacy and security issues, data owners fail to realize the
incentives underlying the sharing of their data. To overcome
this in the future, financing projects should include clear
guidelines to mandate the anonymous sharing of data for
research purposes. Including these political policies would
shed a new light on the benefits of sharing rare disease patient
data with a broader community, truly unlocking its potential.
6. Conclusions
This work introduces a Semantic Web based layer that
provides a holistic perspective over the wealth of knowledge
stemming from linked patient registries supported by the
growing number of research projects.
Our results are significant in at least three major respects:
(1) the use of a model agnostic system, which enables the
mapping of patient registries’ data from any format to a
common shared ontology; (2) the creation of an independent
system that can be plugged into any existing patient registry
without changing it; this enables the extraction of relevant
data elements while maintaining patients’ data privacy and
security; (3) the adoption of Semantic Web technologies to
promote a better translation, interpretation, federation, and
discovery of new knowledge acquired from linked patient
registries datasets.
Finally, this solution enables performing distributed
queries to a federated system of linked patient registries. As
a result, researchers can easily access a broad set of patient
registries just like they would access a single system. We
believe this is a milestone towards semantic interoperable
rare diseases knowledge and will bring us one step closer to
personalized medicine.
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